$BioXcel Therapeutics (BTAI.US)$ NEWS BioXcel Therapeutics A...
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeting. The trial is being led by investigators at Georgetown University’s Lombardi Comprehensive Cancer Center. BXCL701 is an investigational oral innate immune activator designed to inflame the tumor microenvironment and enhance checkpoint inhibitors' activity. BioXcel Therapeutics completed patient enrollment in the safety lead-in portion of the trial on February 6, 2024. The poster presentation titled 'Phase 2 Trial of BXCL701 and Pembrolizumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma' is scheduled for June 1, 2024. Dr. Benjamin Weinberg from the Lombardi Comprehensive Cancer Center will present the preliminary findings at the poster session.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7416Visitors
Follow